# A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

> **NCT07483450** · PHASE4 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 60 (estimated)

## Conditions studied

- Relapsing Multiple Sclerosis
- Primary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Ocrelizumab

## Key facts

- **NCT ID:** NCT07483450
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-04
- **Primary completion:** 2027-03-12
- **Final completion:** 2027-04-23
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07483450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07483450, "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis". Retrieved via MORVS 2026-10-06 from https://api.morvs.ai/clinical/NCT07483450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*